Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (3660)	9/17/1999 10:00:00 AM
From: Mad2	Respond to of 10293

Valid point.

To: JDN who wrote (3660)	9/17/1999 10:06:00 AM
From: out_of_the_loop	Respond to of 10293

I think both your post and Kevin's post have merit. While the free publicity generated by an NEJM or JAMA citation is almost priceless, I personally would not base a long term investment on that. A trade (or short) perhaps; in the long term, other market forces will determine the success of Zicam. I choose to believe it will get published there specifically, but as I have said before, if it does not, but if both studies get published in reputable medical journals, the longterm effect should not be materially different. It is partially a question of one's timeframe. Bill is reputed to not mind long term shorts - and I have stated my personal horizons as the end of the year (GUMM's stated projection at the shareholder meeting) for nicotine gum and mid-to-end of cold season to judge Zicam, its marketing and sales.